drugset
drugset / Trial / NCT02262715

A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir

NCT02262715 ↗

Phase 1 Completed 38 enrolled Janssen Infectious Diseases BVBA
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to investigate the drug-drug interaction between VX-787 and oseltamivir, when co-administered at steady-state in healthy participants. In addition the safety, tolerability and pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of VX-787 will be assessed.

Timeline

Start
2014-07
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Oseltamivir Small molecule 75 mg Oral
Subject Pimodivir Small molecule 600 mg Oral

Indications

No indication recorded.